Compare XAIR & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | CDT |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.9M |
| IPO Year | 2015 | N/A |
| Metric | XAIR | CDT |
|---|---|---|
| Price | $0.38 | $0.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 228.3K | ★ 2.6M |
| Earning Date | 06-16-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,705,000.00 | N/A |
| Revenue This Year | $122.00 | N/A |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.37 |
| 52 Week High | $3.78 | $11.00 |
| Indicator | XAIR | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 33.65 | 33.48 |
| Support Level | N/A | $0.49 |
| Resistance Level | $0.59 | $1.22 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 3.71 | 2.01 |
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.